Your browser doesn't support javascript.
loading
Prevention of dementia using mobile phone applications (PRODEMOS): a multinational, randomised, controlled effectiveness-implementation trial.
Moll van Charante, Eric P; Hoevenaar-Blom, Marieke P; Song, Manshu; Andrieu, Sandrine; Barnes, Linda; Birck, Cindy; Brooks, Rachael; Coley, Nicola; Eggink, Esmé; Georges, Jean; Hafdi, Melanie; van Gool, Willem A; Handels, Ron; Hou, Haifeng; Lyu, Jihui; Niu, Yixuan; Song, Libin; Wang, Wenzhi; Wang, Youxin; Wimo, Anders; Yu, Yueyi; Zhang, Jinxia; Zhang, Wei; Brayne, Carol; Wang, Wei; Richard, Edo.
Afiliação
  • Moll van Charante EP; Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. Electronic address: e.p.mollvancharante@amsterdamumc.nl.
  • Hoevenaar-Blom MP; Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Song M; Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China; School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
  • Andrieu S; Aging Research Team, Centre for Epidemiology and Research in Population Health, INSERM-University of Toulouse UPS, Toulouse, France; Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France.
  • Barnes L; Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Birck C; Alzheimer Europe, Luxembourg, Luxembourg.
  • Brooks R; Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Coley N; Aging Research Team, Centre for Epidemiology and Research in Population Health, INSERM-University of Toulouse UPS, Toulouse, France; Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France.
  • Eggink E; Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Georges J; Alzheimer Europe, Luxembourg, Luxembourg.
  • Hafdi M; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • van Gool WA; Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Handels R; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden; Faculty of Health, Medicine, and Life Sciences Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Maastricht Unive
  • Hou H; Centre for Precision Health, Edith Cowan University, Perth, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia; School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Lyu J; Centre for Cognitive Disorders, Beijing Geriatric Hospital, Beijing, China.
  • Niu Y; Department of Geriatrics, The Second Medical Centre & National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
  • Song L; Comvee Research Institute, Fuzhou Comvee Network & Technology, Fuzhou, China.
  • Wang W; Department of Neuroepidemiology, Beijing Neurosurgical Institute, Beijing, China.
  • Wang Y; Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China; Centre for Precision Health, Edith Cowan University, Perth, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
  • Wimo A; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Yu Y; Innovation Centre for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Zhang J; Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China; Centre for Precision Health, Edith Cowan University, Perth, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
  • Zhang W; Centre for Cognitive Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Brayne C; Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Wang W; Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China; Centre for Precision Health, Edith Cowan University, Perth, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia; School of Public Healt
  • Richard E; Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.
Lancet Healthy Longev ; 5(6): e431-e442, 2024 06.
Article em En | MEDLINE | ID: mdl-38763155
ABSTRACT

BACKGROUND:

The expected increase of dementia prevalence in the coming decades will mainly be in low-income and middle-income countries and in people with low socioeconomic status in high-income countries. This study aims to reduce dementia risk factors in underserved populations at high-risk using a coach-supported mobile health (mHealth) intervention.

METHODS:

This open-label, blinded endpoint, hybrid effectiveness-implementation randomised controlled trial (RCT) investigated whether a coach-supported mHealth intervention can reduce dementia risk in people aged 55-75 years of low socioeconomic status in the UK or from the general population in China with at least two dementia risk factors. The primary effectiveness outcome was change in cardiovascular risk factors, ageing, and incidence of dementia (CAIDE) risk score from baseline to after 12-18 months of intervention. Implementation outcomes were coverage, adoption, sustainability, appropriateness, acceptability, fidelity, feasibility, and costs assessed using a mixed-methods approach. All participants with complete data on the primary outcome, without imputation of missing outcomes were included in the analysis (intention-to-treat principle). This trial is registered with ISRCTN, ISRCTN15986016, and is completed.

FINDINGS:

Between Jan 15, 2021, and April 18, 2023, 1488 people (601 male and 887 female) were randomly assigned (734 to intervention and 754 to control), with 1229 (83%) of 1488 available for analysis of the primary effectiveness outcome. After a mean follow-up of 16 months (SD 2·5), the mean CAIDE score improved 0·16 points in the intervention group versus 0·01 in the control group (mean difference -0·16, 95% CI -0·29 to -0·03). 1533 (10%) invited individuals responded; of the intervention participants, 593 (81%) of 734 adopted the intervention and 367 (50%) of 734 continued active participation throughout the study. Perceived appropriateness (85%), acceptability (81%), and fidelity (79%) were good, with fair overall feasibility (53% of intervention participants and 58% of coaches), at low cost. No differences in adverse events between study arms were found.

INTERPRETATION:

A coach-supported mHealth intervention is modestly effective in reducing dementia risk factors in those with low socioeconomic status in the UK and any socioeconomic status in China. Implementation is challenging in these populations, but those reached actively participated. Whether this intervention will result in less cognitive decline and dementia requires a larger RCT with long follow-up.

FUNDING:

EU Horizon 2020 Research and Innovation Programme and the National Key R&D Programmes of China. TRANSLATION For the Mandarin translation of the abstract see Supplementary Materials section.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Telemedicina / Demência / Aplicativos Móveis Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Asia / Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Telemedicina / Demência / Aplicativos Móveis Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Asia / Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article